Raia Drogasil SA Stock Sao Paulo
Stocks
DROG3
BRDROGACNOR1
Drug Retailers
OTC Markets Traded|
End-of-day quote
Sao Paulo
|
||
| - BRL | - |
|
| Aug. 05 | Raia Drogasil S.A., Q2 2026 Earnings Call, Aug 05, 2026 | |
| Aug. 04 | Raia Drogasil S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 34.1B 6.63B 5.82B 5.47B 5B 9.34B 635B 9.41B 65.66B 25.45B 324B 24.88B 24.34B 1,049B | P/E 2026 * |
22.8x | P/E 2027 * | 17.1x |
|---|---|---|---|---|---|
| Enterprise Value | 42.22B 8.21B 7.2B 6.77B 6.19B 11.57B 786B 11.65B 81.31B 31.52B 401B 30.81B 30.14B 1,299B | EV / Sales 2026 * |
0.93x | EV / Sales 2027 * | 0.83x |
| Free-Float |
73.04% | Yield 2026 * |
1.95% | Yield 2027 * | 2.22% |
Last Transcript: Raia Drogasil SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2024-12-31 | |
| Director of Finance/CFO | 63 | 2013-04-28 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 50 | 2024-12-31 | |
| Director/Board Member | - | - | |
Gilberto Lerio
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.61% | -3.61% | +8.69% | -27.49% | 6.63B | |
| -0.53% | -1.67% | -21.88% | +23.18% | 1.23B | |
| -0.17% | -1.59% | +16.72% | +25.67% | 557M | |
| -0.14% | -0.04% | -12.27% | +26.35% | 66.23M | |
| Average | -1.11% | -0.77% | -2.19% | +11.93% | 2.12B | |
| Weighted average by Cap. | -2.91% | -3.23% | +4.63% | -16.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45.44B 8.83B 7.75B 7.29B 6.66B 12.45B 846B 12.54B 87.5B 33.92B 431B 33.16B 32.43B 1,398B | 51.92B 10.09B 8.86B 8.32B 7.61B 14.22B 967B 14.33B 99.99B 38.76B 493B 37.89B 37.06B 1,598B |
| Net income | 1.51B 293M 257M 242M 221M 413M 28.1B 417M 2.91B 1.13B 14.33B 1.1B 1.08B 46.45B | 2.02B 393M 345M 324M 296M 554M 37.62B 558M 3.89B 1.51B 19.18B 1.47B 1.44B 62.18B |
| Net Debt | 8.13B 1.58B 1.39B 1.3B 1.19B 2.23B 151B 2.24B 15.65B 6.07B 77.13B 5.93B 5.8B 250B | 9.02B 1.75B 1.54B 1.45B 1.32B 2.47B 168B 2.49B 17.36B 6.73B 85.56B 6.58B 6.44B 277B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RADL3 Stock
- DROG3 Stock
Select your edition
All financial news and data tailored to specific country editions
